Guardant Health
Leading liquid biopsy company providing blood-based cancer detection, treatment selection, and monitoring tests. Publicly traded on NASDAQ (GH) with FDA-approved products.
Notes
Guardant Health is a leading precision oncology company pioneering liquid biopsy technology for cancer detection, treatment selection, and disease monitoring. The company's tests analyze circulating tumor DNA (ctDNA) from simple blood draws, providing a less invasive alternative to tissue biopsies.
The company went public on NASDAQ (ticker: GH) in October 2018 and has grown to become one of the largest liquid biopsy companies globally. Guardant's flagship products include Guardant360 for advanced cancer patients and Shield for early colorectal cancer detection.
In 2024, Guardant Shield became the first FDA-approved blood test for colorectal cancer screening in average-risk adults, marking a major milestone for the liquid biopsy field.
Team
- Helmy Eltoukhy, Ph.D. - Co-founder & CEO
- LinkedIn: linkedin.com/in/helmyeltoukhy
- AmirAli Talasaz, Ph.D. - Co-founder & President
- LinkedIn: linkedin.com/in/amirali-talasaz
- Craig Eagle, M.D. - Chief Medical Officer
Additional Research Findings
- Founded in 2012, headquartered in Redwood City, CA
- Public company on NASDAQ (ticker: GH) since October 2018
- Market cap exceeds $3 billion
- Guardant360: liquid biopsy for advanced cancer
- Guardant Shield: FDA-approved colorectal cancer screening (2024)
- Revenue over $500 million annually
- Key investors included Sequoia Capital, Khosla Ventures, and others
- Employs approximately 2,000+ people
- CLIA-certified laboratory in Redwood City
- Strategic partnerships with major pharmaceutical companies
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sequoia Capital | Menlo Park, California, USA | generalist | seedseries-a+3 | 4 |
| Lightspeed Venture Partners | Menlo Park, California, USA | generalist | seedseries-a+3 | 3 |